Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹7,875 Cr
down ₹389 Cr vs Dec 2025
- Stocks held
- 35
- down 1 vs Dec 2025
- Top 10 weight
- 58.1%
- of the portfolio in its ten largest
- Cash & debt
- 1.0%
- cash, money market and debt
- Moves this month
- 0 in · 1 out
- added to 9, trimmed 25
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In January 2026 it disclosed 35 stocks worth ₹7,875 Cr, down ₹389 Cr from Dec 2025. Its largest positions were Sun Pharmaceutical Industries Limited (12.7%), Lupin Limited (7.9%), Divi's Laboratories Limited (6.5%); the ten largest together made up 58.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 74.6% of its equity. Cash and debt stood at 1.0%. Compared with Dec 2025 the fund entered 0 new stocks and exited 1.
Against 226 other Sectoral / Thematic funds
Concentration
79%
Top-10 weight is higher than 79% of peers
Breadth
26%
Holds more stocks than 26% of peers
Cash
13%
Holds more cash than 13% of peers
Holdings in January 2026
Download CSVEvery line the fund disclosed, with the change against Dec 2025. Click a column to sort; click a company to see every fund that owns it.
- Weight
- 12.67%
- Δ weight
- down 0.34 pts
- Value
- ₹998 Cr
- Δ value
- down ₹77.8 Cr
- Status
- Trimmed
- Weight
- 7.88%
- Δ weight
- up 0.52 pts
- Value
- ₹621 Cr
- Δ value
- up ₹12.5 Cr
- Status
- Added
- Weight
- 6.54%
- Δ weight
- down 0.04 pts
- Value
- ₹515 Cr
- Δ value
- down ₹29.1 Cr
- Status
- Trimmed
- Weight
- 6.06%
- Δ weight
- up 0.03 pts
- Value
- ₹477 Cr
- Δ value
- down ₹20.9 Cr
- Status
- Trimmed
- Weight
- 5.88%
- Δ weight
- down 0.52 pts
- Value
- ₹463 Cr
- Δ value
- down ₹65.5 Cr
- Status
- Trimmed
- Weight
- 5.73%
- Δ weight
- up 0.21 pts
- Value
- ₹452 Cr
- Δ value
- down ₹5.3 Cr
- Status
- Trimmed
- Weight
- 3.68%
- Δ weight
- up 0.14 pts
- Value
- ₹290 Cr
- Δ value
- down ₹3 Cr
- Status
- Trimmed
- Weight
- 3.51%
- Δ weight
- down 0.19 pts
- Value
- ₹277 Cr
- Δ value
- down ₹29.5 Cr
- Status
- Trimmed
- Weight
- 3.39%
- Δ weight
- up 0.17 pts
- Value
- ₹267 Cr
- Δ value
- up ₹1.2 Cr
- Status
- Held
- Weight
- 2.78%
- Δ weight
- up 0.05 pts
- Value
- ₹219 Cr
- Δ value
- down ₹6.6 Cr
- Status
- Trimmed
- Weight
- 2.71%
- Δ weight
- down 0.10 pts
- Value
- ₹213 Cr
- Δ value
- down ₹18.7 Cr
- Status
- Trimmed
- Weight
- 2.61%
- Δ weight
- up 0.17 pts
- Value
- ₹206 Cr
- Δ value
- up ₹4.2 Cr
- Status
- Added
- Weight
- 2.60%
- Δ weight
- down 0.01 pts
- Value
- ₹204 Cr
- Δ value
- down ₹10.8 Cr
- Status
- Trimmed
- Weight
- 2.55%
- Δ weight
- up 0.50 pts
- Value
- ₹201 Cr
- Δ value
- up ₹31.3 Cr
- Status
- Added
- Weight
- 2.45%
- Δ weight
- up 0.43 pts
- Value
- ₹193 Cr
- Δ value
- up ₹26.3 Cr
- Status
- Added
- Weight
- 2.37%
- Δ weight
- up 0.17 pts
- Value
- ₹187 Cr
- Δ value
- up ₹5 Cr
- Status
- Added
- Weight
- 2.34%
- Δ weight
- down 0.03 pts
- Value
- ₹184 Cr
- Δ value
- down ₹11.3 Cr
- Status
- Trimmed
- Weight
- 2.33%
- Δ weight
- up 0.18 pts
- Value
- ₹184 Cr
- Δ value
- up ₹5.5 Cr
- Status
- Added
- Weight
- 2.18%
- Δ weight
- down 0.01 pts
- Value
- ₹172 Cr
- Δ value
- down ₹8.9 Cr
- Status
- Trimmed
- Weight
- 2.07%
- Δ weight
- down 0.04 pts
- Value
- ₹163 Cr
- Δ value
- down ₹11.5 Cr
- Status
- Trimmed
- Weight
- 1.88%
- Δ weight
- up 0.21 pts
- Value
- ₹148 Cr
- Δ value
- up ₹10 Cr
- Status
- Added
- Weight
- 1.84%
- Δ weight
- down 0.08 pts
- Value
- ₹145 Cr
- Δ value
- down ₹13.5 Cr
- Status
- Trimmed
- Weight
- 1.51%
- Δ weight
- up 0.38 pts
- Value
- ₹119 Cr
- Δ value
- up ₹25.6 Cr
- Status
- Added
- Weight
- 1.39%
- Δ weight
- up 0.16 pts
- Value
- ₹109 Cr
- Δ value
- up ₹7.4 Cr
- Status
- Added
- Weight
- 1.32%
- Δ weight
- up 0.04 pts
- Value
- ₹104 Cr
- Δ value
- down ₹1.4 Cr
- Status
- Trimmed
- Weight
- 1.19%
- Δ weight
- up 0.01 pts
- Value
- ₹94 Cr
- Δ value
- down ₹3.6 Cr
- Status
- Trimmed
- Weight
- 1.17%
- Δ weight
- up 0.04 pts
- Value
- ₹92.5 Cr
- Δ value
- down ₹1.6 Cr
- Status
- Trimmed
- Weight
- 1.15%
- Δ weight
- down 0.02 pts
- Value
- ₹90.7 Cr
- Δ value
- down ₹5.8 Cr
- Status
- Trimmed
- Weight
- 1.13%
- Δ weight
- up 0.04 pts
- Value
- ₹89.2 Cr
- Δ value
- down ₹70 L
- Status
- Trimmed
- Weight
- 1.03%
- Δ weight
- down 0.02 pts
- Value
- ₹81.4 Cr
- Δ value
- down ₹6 Cr
- Status
- Trimmed
- Cash, TREPS & receivables
- Weight
- 1.03%
- Δ weight
- down 1.60 pts
- Value
- ₹81.3 Cr
- Δ value
- down ₹136 Cr
- Status
- Trimmed
- Weight
- 0.85%
- Δ weight
- up 0.01 pts
- Value
- ₹66.6 Cr
- Δ value
- down ₹2.1 Cr
- Status
- Trimmed
- Weight
- 0.81%
- Δ weight
- down 0.03 pts
- Value
- ₹63.4 Cr
- Δ value
- down ₹5.5 Cr
- Status
- Trimmed
- Weight
- 0.68%
- Δ weight
- down <0.01 pts
- Value
- ₹53.5 Cr
- Δ value
- down ₹3 Cr
- Status
- Trimmed
- Weight
- 0.51%
- Δ weight
- down 0.01 pts
- Value
- ₹39.9 Cr
- Δ value
- down ₹3.1 Cr
- Status
- Trimmed
- Weight
- 0.17%
- Δ weight
- down 0.02 pts
- Value
- ₹13.1 Cr
- Δ value
- down ₹1.9 Cr
- Status
- Trimmed
What changed, Dec 2025 to Jan 2026
New New positions (0)
None.
Exited Exited (1)
- Orchid Pharma Limitedwas 0.4% · ₹34.7 Cr
Added Biggest additions
- IPCA Laboratories Limitedup ₹31.3 Cr (+0.50% pts)
- Mankind Pharma Limitedup ₹26.3 Cr (+0.43% pts)
- Max Healthcare Institute Limitedup ₹25.6 Cr (+0.38% pts)
- Lupin Limitedup ₹12.5 Cr (+0.52% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Dec 2025, the weight fell most in Pharmaceuticals & Biotechnology (−0.1 pts).
- Pharmaceuticals & Biotechnology74.7% → 74.6%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jan 2023 | Jan 2025 | Jul 2025 | Oct 2025 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.2% | 77.0% | 75.5% | 74.7% | 74.7% | 74.6% |
| Healthcare Services | 18.9% | 19.2% | 20.0% | 21.3% | 21.1% | 21.2% |
| Retailing | 1.2% | 3.2% | 3.9% | 3.3% | 3.6% | 3.7% |
| Pharmaceuticals | 1.4% | 0.6% | 0.7% | 0.6% | 0.5% | 0.5% |
Allocation in Jan 2026change vs Dec 2025
- Pharmaceuticals & Biotechnology (24)74.6%▼ 0.1 pts
- Healthcare Services (9)21.2%▲ 0.1 pts
- Retailing (1)3.7%▲ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Jan 2026
1.0%
▼ 1.6 pts vs Dec 2025
- Cash alone
- 1.0%
- cash and net receivables
- A year earlier
- 1.4%
- Jan 2025 · now ▼ 0.3 pts
- Last 12 months
- 0.3% – 2.6%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.